Kinetics of hepatitis B surface antigen quasispecies during REP 2139‐Ca therapy in HBeAg‐positive chronic HBV infection-Reference-Cited by-同舟云学术

Kinetics of hepatitis B surface antigen quasispecies during REP 2139‐Ca therapy in HBeAg‐positive chronic HBV infection

Published:2019-08-13 Issue:12 Volume:26 Page:1454-1464
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Usman Zainab¹,Mijočević Hrvoje²,Karimzadeh Hadi²³,Däumer Martin⁴,Al‐Mathab Mamun⁵,Bazinet Michel⁶,Frishman Dmitrij¹⁷,Vaillant Andrew⁶,Roggendorf Michael²^ORCID

Affiliation:

1. Department of Bioinformatics Technische Universität München, Wissenschaftszentrum Weihenstephan Freising Germany

2. Institute of Virology Technische Universität München Munich Germany

3. Department of Medicine II University Hospital Munich‐Grosshadern Munich Germany

4. Institute of Immunology and Genetics Kaiserslautern Germany

5. Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh

6. Replicor Inc. QC Canada

7. Laboratory of Bioinformatics, RASA research center St Petersburg State Polytechnical University Saint Petersburg Russia

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13180

Reference41 articles.

1. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2. WHO.Hepatitis B fact sheet updated: World Health Organization.2017.

3. Viruses as Quasispecies: Biological Implications

4. The quasispecies nature and biological implications of the hepatitis C virus

5. Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive Patients

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigen;PLOS ONE;2023-11-01

2. Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation;ACS Medicinal Chemistry Letters;2021-06-22

3. Hepatitis B virus: promising drug targets and therapeutic implications;Expert Opinion on Therapeutic Targets;2021-04-19

4. Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B;Internal Medicine;2021-02-15

5. SASLT practice guidelines for the management of Hepatitis B virus – An update;Saudi Journal of Gastroenterology;2021